GVS (GVS) H1 2024 earnings summary

Executive summary

• Consolidated revenues for H1 2024 reached €214.8 million, up 1.6% year-over-year at constant exchange rates, led by strong Health & Safety division growth and stable Healthcare & Life Sciences performance.

• Adjusted EBITDA rose 10.6% to €52 million, with margin improving to 24.2% in H1 and 25% in Q2 2024.

• Adjusted net income increased 12.3% to €22.5 million, with margin at 10.5%.

• Net financial position improved to €241.6 million, with leverage ratio at 2.42x, down from 2.65x at year-end 2023.

• Net income reached €19 million, reflecting improved profitability and lower effective tax rate.

Financial highlights

• Revenue: €214.8 million (+1.6% at constant exchange rates year-over-year).

• Adjusted EBITDA: €52 million (24.2% margin), up from €47.1 million (22.1% margin) in H1 2023.

• Adjusted EBIT: €37.7 million (17.5% margin), up 11.6% year-over-year.

• Adjusted net income: €22.5 million, up 12.3% year-over-year; net income: €19 million.

• Adjusted net financial debt at €241.6 million as of June 2024, down €10.6 million from December 2023.

Outlook and guidance

• Full-year 2024 adjusted EBITDA margin guidance revised upwards to an increase of 150–250 basis points over 2023.

• Low- to mid-single-digit consolidated turnover growth expected for FY 2024.

• High single-digit sales growth anticipated in Q3 2024 versus Q3 2023.

• Adjusted leverage ratio expected to be around 2x at year-end 2024.